MARC Record from Library of Congress

LEADER: 01742nam a22003138a 4500
001 2009013524
003 DLC
005 20090407150057.0
008 090330s2009 nyu b 001 0 eng
010 $a 2009013524
020 $a9781607415930 (hardcover : alk. paper)
035 $a(DNLM)101500490
040 $aDNLM/DLC$cDLC
042 $apcc
050 00 $aRC280.B8$bL2715 2009
060 10 $aWP 870$bL147m 2009
082 00 $a362.196/99449$222
100 1 $aLacroix, Marc,$d1963-
245 10 $aMolecular therapy of breast cancer :$bclassicism meets modernity /$cMarc Lacroix.
260 $aHauppauge, NY :$bNova Science,$cc2009.
263 $a0909
300 $ap. ;$ccm.
504 $aIncludes bibliographical references and index.
505 0 $aIntroduction -- Selective estrogen receptor modulators (SERMS) and down-regulators (SERDS) -- Aromatase inhibitors -- Agents inducing ovarian suppression -- Antimetabolites -- Alkylating agents -- Anthracyclines -- Microtubule-binding agents -- Topoisomerase inhibitors -- HER family inhibitors -- Angiogenesis inhibitors -- Insulin-like growth factor-I receptor inhibitors -- RAS-RAF-MEK-ERK pathway inhibitors -- Ubiquitin-proteasome system inhibitors -- Histone deacetylases inhibitors -- Mitotic inhibitors -- Inhibitors of heat-shock proteins 90 and 27 -- PI3K/AKT/MTOR pathway inhibitors -- Cyclooxygenase-2 inhibitors -- Poly(ADP-RIBOSE) polymerase (PARP)-1 inhibitors -- Tumor-induced osteolysis inhibitors -- Vaccines and immunomodulators -- Varia.
650 0 $aBreast$xCancer$xMolecular aspects.
650 0 $aAntineoplastic agents.
650 12 $aBreast Neoplasms$xdrug therapy.
650 22 $aAntineoplastic Agents$xtherapeutic use.
650 22 $aEnzyme Inhibitors$xtherapeutic use.